Related references
Note: Only part of the references are listed.Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
Satoshi Motoya et al.
PLOS ONE (2019)
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
James D. Lewis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review
Christopher Ma et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
Xue-Liang Jiang et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2015)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Dose-related patterns of glucocorticoid-induced side effects
D. Huscher et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
